Transcriptional profiling using cDNA or oligonucleotide microarrays has proven a powerful technique to obtain genome-wide information on gene expression. Profiling of tumors has unveiled the signature of malignant transformation, identified predictive gene expression profiles, and allowed novel disease classifications. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, array analysis of whole tumors offers only limited insights into molecular events in individual cell subtypes within tumors. Established cell lines, tumor derived primary cell cultures, and immunopurified cells procured through tissue dissociation and cell sorting have been studied as surrogates. [10] [11] [12] [13] [14] [15] [16] However, such studies are limited by flaws related to artificial in vitro conditions, prolonged propagation, and/or stressful purification procedures, all of which are expected to induce marked changes in the transcriptome, as cells are deprived from their natural metabolic, paracrine, endocrine and immune milieu, and lose critical adhesive interactions affecting their function in the tumor microenvironment.
The use of laser capture microdissection (LCM) to isolate tumor islets 5, 17 provides a limited advantage, eliminating stroma surrounding tumor islets. However, as tumor islets in the majority of adult solid tumors are infiltrated by a variety of host cells, [18] [19] [20] transcription profiles of tumor islets are likely to represent tumor cells and tumor-infiltrating inflammatory and vascular cells, making interpretation of results difficult.
Immunohistochemistry-guided LCM (immuno-LCM) has been used to isolate pure populations of cells procured from tumors. This technique has been devised to isolate distinct cell populations from their natural environment in situ not only according to morphology but also to immunophenotype criteria. [21] [22] [23] It has been used successfully for PCR-based gene analysis of specific cell populations in brain tissue, [24] [25] [26] brain vessels 27 and epithelial cells, 28, 29 but to our knowledge has never been employed for genome-wide discovery. A major limitation has been the necessity to procure high quality and sufficient quantity of RNA.
We modified prior techniques, combining and carefully optimizing immuno-LCM, RNA isolation and amplification to perform for the first time genome-wide transcriptional profiling of immuno-LCM isolated tumor-derived cell populations. The methodology is simple, rapid, sensitive and specific, and allowing detailed study of specific cellular populations in situ. Immuno-LCM represents a new tool for studying the individual components of the tumor microenvironment in situ.
Real-time PCR. PCR was performed using primers to the 3' end of transcripts spanning intron-exon boundaries whenever possible (Supplemental Table 2 ). PCR was performed for 35 cycles using Sybergreen (ABI, Foster City, CA) as recommended by the manufacturer, with primers at 150 nM concentrations. All transcripts were confirmed using 3% agarose gel electrophoresis and sequenced.
Immunostaining. IHC for gene validation was performed using the LSAB2 kit (DAKO) according to manufacturer's instructions. Monoclonal antibodies against IKKβ (clone 24, BD Biosciences, San Jose, CA) and c-Jun (clone 3, BD Biosciences) were used according to manufacturers' instructions.
Statistical and bioinformatics analyses. The analyses of expression profiles were performed using Genespring software (Agilent). All samples were normalized with the median defined as 1.0. Pearson's correlation coefficients were computed to assess correlation between gene expression profiles from different amplifications within the same experiment or in different experiments. Unsupervised hierarchical clustering (Genespring) was performed using a list of all genes that were found to be present in at least one sample, to generate a heat map condition tree comparing the expression profiles of microdissected tumor cells and whole tumor islets from which they were isolated. Statistical significance for mRNA expression differences among sample types was determined using analysis of variance (ANOVA) with p < 0.05 considered as significant. EASE pathway (http://david.niaid.nih.gov/ david/ease.htm) and Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA) were used to identify gene function and implicated pathways. Genes involved in the nuclear factor kappa-B (NF-κB) pathway were obtained from NCI's Cancer Genome Anatomy Project website (http:// cgap.nci.nih.gov/Pathways/BioCarta_Pathways). This list of 22 genes was cross-referenced with 22,283 probe sets on Affymetrix U133A arrays. Thirtythree matching probe sets were identified. Recursive partitioning (CART, Salford Systems, San Diego, CA) was used to identify genes that could classify tumor cells in situ from cultured cell line.
RESULTS

Optimization of immunostaining.
Fixation. To procure purified cell populations for microarray applications we optimized a rapid and reliable protocol of immuno-LCM. We first tested different fixation conditions (Fig. 1A ) including ethanol; methanol; acetone; or 4% paraformaldehyde in PBS. In agreement with a previous report, 30 fixation with ethanol, or acetone resulted in the greatest RNA yield (Fig. 1A) . However, ethanol did not allow optimal IHC visualization of select target proteins (Supplemental Table 1 and data not shown). We also tested RNAlater used prior to fixation. While IHC was possible using RNAlater, tissue integrity was reduced and RNA yields were not increased (data not shown). Thus, we chose acetone fixation for all further experiments.
Immunostaining. Next, we optimized immunostaining. RNA isolated from tissue sections after standard IHC using LSAB (DAKO) or Vectastain (Vector) showed near-complete degradation (Fig. 1B , right lane, and data not shown). We thus developed an ultra-fast IHC protocol by increasing antibody concentration to 1:10 and staining for only 5 minutes. We also increased the concentration of Streptavidin amplification complex to 2.5X. Other attempts to improve staining efficiency, including the use of Hrp/Fab polymer conjugates (Zymed laboratories and DAKO Envision system) yielded suboptimal staining and did not improve RNA yield compared to ultra-rapid IHC using AEC (data not shown).
Addition of high concentration of RNAse inhibitors (2 U/µl) to IHC steps was necessary for preservation of RNA integrity. The choice of RNAse inhibitor was critical; RNA Protector (Roche) was found to be superior to placental RNAse inhibitor (Stratagene) or SuperRNAsin (Ambion), leading to two-fold increase in RNA yield and integrity. Combining RNA Protector with other RNAse inhibitors reduced the efficacy of RNA Protector (data not shown). RNA Protector allowed for 90% preservation of RNA integrity relative to no immunostaining (Fig. 1B) .
Detection. Next, we compared detection systems (Fig. 1C) . AEC chromagen resulted in 40% greater RNA yield than DAB. Immunofluorescence (IF) resulted in 100% increased RNA yield compared to AEC (Fig. 1C) , but contaminating cells were poorly identifiable without counterstaining. This resulted in decreased purity of microdissected cells and increased contamination by undesired host cells, as assessed by qRT-PCR detection of the T-cell marker CD3-epsilon (data not shown). Furthermore, fluorescence quenching limited LCM time. Thus, we used IHC with AEC detection for all subsequent experiments.
Duration. Finally, we examined the effect of LCM time on RNA yield and integrity (Fig. 1D) . Extending of LCM up to three hours before RNA isolation had no significant impact on the quality or quantity of RNA isolated. Our current protocol (Table 1) requires approximately 25 minutes for IHC, and is successful for numerous antibodies (supplemental Table 1 ).
Optimization of RNA purification. We compared RNA yield and quality after immuno-LCM to identify a method optimal for RNA isolation (Fig. 1E) . We tested the Arcturus Picopure kit; Stratagene microRNA isolation kit; Zymo mini RNA isolation kit; and the modified TRIzol method for less than 10 5 cells, using protocols as directed by the manufacturers. The Stratagene micro RNA isolation kit and the modified TRIzol method (Fig. 1E ) gave significantly better and similar yields by quantification with the Agilent Bioanalyzer. Conversely, although Arcturus Picopure gave the highest RNA yield for tissues stained with hematoxylin alone (not shown), it performed poorly following IHC as did the protocol from ZYMO (Fig. 1E , and data not shown). RNA quality was tested by real-time PCR quantification of β-actin ( Fig. 1F ) and GAPDH transcripts (not shown) in total RNA procured from 1 x 10 6 tumor cells after immuno-LCM. β-actin transcript was detected at similar levels in RNA isolated with the modified Trizol reagent microprotocol or with the Stratagene micro RNA isolation kit. β-actin levels were significantly lower with the Arcturus picopure (10-fold) and ZYMO RNA isolation kits (256-fold) (Fig. 1F) . Similar results were obtained with GAPDH real-time PCR (not shown). Based on these results, we chose the Trizol reagent microprotocol for further experimentation.
Optimization of RNA amplification. Figure 2 shows that we next tested different amplification protocols. The expression profile of 5 µg of whole tumor RNA was compared to 6, 24 or 60 ng of starting whole tumor RNA following two amplification cycles with Arcturus OA or Ambion MessageAmp kits. The Arcturus kit was associated with faster execution and two fold increase in anti-sense RNA (aRNA) yield for the lowest amount of RNA tested, but resulted in 3' skewing, with 3':5' ratio of 20-40:1 ( Fig. 2A,  bottom) . Ambion MessageAmp yielded greater 5' representation, with 3':5' ratio of 6-16:1, but a lower overall aRNA recovery ( Fig. 2A) . Approximately 45-55% of genes comprised in Affymetrix U133A chips were classified as "present" by MAS5.0 Suite (Affymetrix) with either protocol, when starting whole tumor RNA was greater than 20 ng. With 6 ng starting RNA, 5-10% fewer genes were detected with Ambion than with Arcturus protocol. Based on improved 5':3' representation, we used Ambion MessageAmp for further experimentation. Next, we tested whether RNA isolated through immuno-LCM and the modified TRIzol method could be amplified linearly for transcriptional profiling using the Ambion MessageAmp protocol. The expression profile of 5 µg of unamplified whole tumor RNA was compared to the expression profile of 6, 24 or 60 ng of amplified RNA using Affymetrix U133A chip. Correlation between unamplified RNA and 24 or 60 ng starting RNA was high (r = 0.93 and 0.94, respectively) (Fig. 2B, left) . Correlation was lower with 6 ng starting RNA (r = 0.87; data not shown). Importantly, IHC or immuno-LCM had no impact on expression profile (r = 0.98; Fig. 2B,  right) . Finally, a high correlation was found between gene expression profiles of 60 ng RNA from the same tumor amplified within the same experiment (intra-assay correlation, r = 0.99) or at different times (inter-assay correlation, r = 0.97) (data not shown).
Specificity of immuno-LCM purified tumor cells. We have previously shown that ovarian cancer tumor islets are infiltrated by a brisk inflammatory infiltrate including T cells. 18 To test the ability of the rapid immuno-LCM protocol developed above to isolate pure populations of cells from ovarian cancers, we employed it to isolate tumor cells or tumor vascular endothelial cells from tumor islets heavily infiltrated by host immune cells. Tumor cells were selected employing CD31 and CD45 double IHC, and dissecting large CD31/CD45 double-negative cells from tumor islets (Fig. 3A, top row) . Tumor vascular endothelial cells were selected employing CD31 IHC and dissecting CD31 + cells with elongated vascular morphology (Fig. 3A, bottom  row) . Whole tumor islets from the same specimens were microdissected from surrounding stroma based on morphology as controls.
The purity of microdissection was tested by standard or quantitative real-time RT-PCR (qRT-PCR) of lineage-specific transcripts (Fig. 3B and C) . RT-PCR analysis of RNA from purified tumor vascular endothelial cells (TECs) confirmed the absence of CD3-ε and CD5 (T cells); CD16 (NK cells); CD19 and CD20 (B cells); and cytokeratin-18 (epithelial cell marker) (Fig. 3B) . Interestingly, we detected low level expression of the hematopoietic/ myeloid markers CD11c (Fig. 3B), CD45 (Fig. 3C) and CD14 (not shown), consistent with previous evidence for monocytic origin of vascular cell precursors in ovarian cancer. 31 qRT-PCR revealed a 15-fold enrichment of CD31 mRNA in microdissected specimens relative to CD31 mRNA in whole tumor. Thus, highly purified populations of specific cellular compartments can be isolated from frozen tumor specimens using this protocol.
A novel transcriptome of tumor cells in vivo is revealed by immuno-LCM.
To test whether immuno-LCM can reveal a novel signature of tumor cells, we compared the in situ gene expression profile of immuno-LCM isolated tumor cells and matched whole tumor islets isolated from four ovarian cancers heavily infiltrated with immune cells. We compared these profiles to in vitro gene expression profile of established ovarian cancer cell line A2780. Unsupervised hierarchical clustering revealed that expression profiles of tumor cells isolated through immuno-LCM from different tumors were more related to each other than they were to matched tumor islets from the parent specimen (Fig. 4A ). This result shows that immuno-LCM captures a distinct gene expression profile that can discern tumor cells from whole tumor islets. This suggests that other cell types (i.e., host cells) significantly contribute to the profile of whole tumor islets. As expected, A2780 cells were distantly related to whole tumor islets. Importantly, they were also distant from purified tumor cells in situ. The difference of these profiles is discussed below.
Tumor cells in situ vs. whole tumor islets. On average 1,797 more genes (range: 1,309-2,173) were classified as "present" in arrays of whole tumor islets relative to matched microdissected tumor cells. This pool of genes, present in tumor islets but absent in microdissected tumor cells, represented approximately 20% of all the genes detected in whole tumor islets. A significant overlap was seen among profiles of tumor islets or microdissected tumor cell samples (Fisher's exact test, p < 0.000005). EASE pathway analysis using GO:biologic function revealed that the majority of genes present in islets and absent from microdissected tumor cells were related to immune function, 
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including antigen processing and presentation; humoral immune response; immune response; and antimicrobial response (Fig. 4B) . Further analysis of genes, which were "present" in tumor islets, identified ~1,400 genes that were expressed at significantly higher levels (ANOVA, p < 0.05) in tumor islets compared to matched tumor cells. Analysis of these 1,400 genes overexpressed in tumor islets relative to tumor cells using Ingenuity Pathway Analysis revealed over-representation of HLA clusters; a lymphocyte signaling pathway (p < 0.0000003); a tumor necrosis factoralpha (TNF-α) death signaling pathway; and vascular signaling pathways (data not shown). Collectively, these results show that the gene expression profile of tumor islets is also contributed by host cells and reflects immune response, tumor inflammation and angiogenesis.
Next we identified, on average, 886 additional genes (range 611-1435) classified as "present" in arrays of microdissected tumor cells but "absent" in matched whole islets. These genes represented approximately 10% of all genes detected in purified tumor cells. Significant overlap was seen among different tumor cell samples analyzed (Fisher's exact test, p < 0.00005). To test whether these genes were indeed expressed by tumors, we quantified expression of four randomly selected genes (desmocollin-2; BRCA-associated protein-1; AW299245 and DDX-17) by qRT-PCR in 20 ovarian cancers (Fig. 4C ). Data were normalized against β-actin. All four transcripts were clearly identified in all tumors. These results show that lower abundance genes detected by immuno-LCM based transcriptional profiling are in fact expressed by tumors. Thus, immuno-LCM increases the sensitivity of gene expression profiling of tumor cell populations.
Tumor cells in situ vs. in vitro. Over 1,400 genes were overexpressed at least 5-fold in cultured A2780 cells compared to microdissected tumor cells in situ. IPA revealed eight pathways significantly overexpressed in the cell line relative to microdissected tumor cells. These were all metabolic, including oxidative phosphorylation; ubiquinone biosynthesis; citrate cycle; pyruvate metabolism; pyrimidine metabolism; purine metabolism; glycolysis; and fatty acid biosynthesis.
Over 1,200 genes were greater than 5-fold overexpressed in tumor cells in situ compared to A2780 cells. IPA revealed several growth factor signaling pathways including insulin-like growth factor-1 (IGF-1); TNF-α; and interleukin-1 (IL-1), all of which converged on the IKK/NF-κB pathway (Fig. 5) , as well as estrogen receptor signaling and c-Jun signaling (p < 0.05, data not shown). Figure 4D shows presence and expression level of select genes involved in the in NF-κB pathway in A2780 cell line (C) and in microdissected tumor cells in vivo (T). These include nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA); TNF-α induced protein 6 (TNFaip); IL-1 receptor (IL-1R); mitogen-activated protein kinase kinase kinase 7 (MAP3K7); tumor necrosis factor receptor superfamily-member 1A (TNFRSF1a); IL-1 alpha (IL-1a) ; myeloid differentiation primary response gene-88 (MYD88); inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB); and inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma (IKBKG).
To further confirm activation of NF-κB and c-Jun signaling, we tested the expression of IKK-β and c-Jun in ovarian cancer by IHC. Immunostaining shows clear tumor cell localization of these two proteins in ovarian cancer specimens (Fig. 4E) . Thus, the genes identified through immuno-LCM based transcriptional profiling are indeed expressed in tumor cells.
As an independent means of confirmation, we used CART to analyze the array data of cultured A2780 cells and microdissected tumor cells for each gene in the NF-κB pathway. These genes were derived from www.biocarta.com. Within the NF-κB pathway, 19 probe sets (14 genes) were able to predict with 100% accuracy tumor cells in situ from cell line replicates (not shown). Sixteen of these 19 probe sets (11 genes) were upregulated in tumor cells in situ, including TNF-α, TNF receptor, IL-1, IL-1 receptor, IκB kinase, and MAP3K7, as shown in Figure 4D .
Sensitivity of the immuno-LCM protocol for tumor vascular cell profiling. In order to test the sensitivity of our protocol for less abundant cell populations, we dissected and profiled 2-4 x 10 3 CD31 + vascular cells from two tumor samples and one normal ovary and compared the results to the expression profile of human umbilical vein endothelial cells (HUVEC). We detected 13 of 13 known pan-endothelial markers in tumor vascular cell arrays. 32, 33 Similarly, 12 of 14 known 'tumor endothelial-specific' markers were detected at high levels in tumor vascular cell arrays (Table 2) confirming greater than 90% sensitivity of our assay with as few as 2,000 microdissected cells. Array analysis of microdissected tumor vascular endothelial cells compared to normal and HUVEC identified 52 genes as greater than 10-fold upregulated in tumor versus normal vascular cells. Comprising the list were numerous previously identified tumor vascular markers including 5 collagen family members, Thy-1, TEM7, nidogen, BMP-1, α1 integrin and versican. However, the majority of the genes identified were novel tumor vascular markers (not shown). Further analysis of ovarian tumor vascular-specific genes based on a larger sample size is necessary to identify biologically meaningful tumor vascular cell profiles and will be presented elsewhere.
Use of Immuno-LCM to Identify the in Situ Expression Profile of Cellular Constituents of the Tumor Microenvironment 
DISCUSSION
We demonstrate a simple and rapid method of immuno-LCM to recover pure cell populations from frozen tumor specimens. Procured RNA is of high quality and can be linearly and reproducibly amplified for array analysis. This protocol offers several advantages over previously described tissue dissociation and cell immunopurification approaches. [32] [33] [34] It is less time consuming; it allows cells to be fixed in their native microenvironment, avoiding transcriptional changes that occur during stressful isolation procedures; and requires minimal amounts of tissue. Finally, archived frozen tissues can be utilized, offering unparalleled opportunities to cross-sectional studies and histopathologic/clinical correlations.
The protocol developed here worked with seven of the eight antibodies tested (Supplemental Table 1 ). We recommend the use of only high titer, high affinity monoclonal antibodies thereby reducing the risk of RNAse exposure and primary incubation time. We found that the RNAse inhibitor acted as an effective block to reduce background so that all antibodies worked at concentrations of 1:10. While most antibodies demonstrated excellent stain with only five minutes of incubation, some primaries required up to 15 minutes of incubation; this had no impact on RNA quality or integrity. The quality of each primary will need to be tested for each specific cell type and tissue of interest. This protocol was developed to work with the MMI Microcut laser-capture microdissection system. A benefit of this system is that the captured cells are not directly exposed to the laser, increasing RNA integrity and retrievability. However, an alternative protocol can be used with the Arcturus system (http://cgap-mf.nih.gov/Protocols/Slides/SlideProtocols/ImmunoL CM.html#Published). This protocol allows isolation of mRNA up to 600 base pairs long. Approximately 500-1000 laser shots will be required to isolate 2000 vascular cells in order to extract 20ng of RNA using this protocol. It is important to note that the optimal RNA amplification protocol following immuno-LCM with this system may differ and need to be tested experimentally.
We used the immuno-LCM protocol to characterize, for the first time the in-situ expression profile of epithelial ovarian cancer cells. Our work highlights that profiling of tumor islets microdissected based on plain morphology does not accurately reflect specific molecular events in tumor cells. Approximately 20% of all genes detected in tumor islets were absent from the transcriptome of purified tumor cells. The high degree of correlation among replicates suggests that this difference was not due to bias introduced by RNA amplification. Furthermore, this was not due to decreased sensitivity following immuno-LCM, as a large number of genes were detected exclusively in arrays from purified tumor cells and not tumor islets. Finally, a large proportion of genes were differentially expressed in tumor islets and tumor cells. This allowed for a clear-cut distinction of the two types of specimens by unsupervised hierarchical clustering.
Signaling pathways regulating cell survival, proliferation and migration are shared by tumor and host cells, making interpretation of molecular signatures difficult in mixed cell samples. The importance of studying purified cell populations is underscored by the identification of NF-κB activation in tumor cells in vivo. NF-κB signaling is active in cancer cells but also in leukocytes and endothelial cells, [35] [36] [37] [38] [39] thus evidence of NF-κB activation in whole tumor islets might not have necessarily reflected tumor cells. This study clearly establishes a significant activation of inflammatory pathways converging on NF-κB in tumor cells in vivo. This was not the case in A2780 cells propagated in vitro. This pathway warrants further investigation in ovarian cancer. Interestingly, NF-κB expression was recently attributed an essential role in tumor progression of inflammation associated cancer. 40 NF-κB activation in tumor cells could also play an important role in facilitating inflammation and immune recognition, as all tumors examined in this study exhibited a brisk intratumoral T cell infiltration. 18 The immuno-LCM protocol described is also suitable for profiling less abundant host populations. Our protocol proved highly specific and over 90% sensitive for both pan-endothelial and tumor endothelial-specific genes. Interestingly, previous studies using an immunopurification approach of tumor endothelial cells necessitated the upfront elimination of CD45 + cells. [32] [33] [34] 41 We and others have recently shown that myeloid vascular precursors expressing monocyte markers play an important role in tumor vasculogenesis, [42] [43] [44] [45] confirming earlier observations. 46 The immuno-LCM protocol described here allows the inclusion of CD45 + vascular cells and therefore may allow for the identification of novel vascular markers from vascular cells of myeloid origin. Further study with a larger sample size will be necessary to test this hypothesis.
In conclusion, the immuno-LCM methods described is suitable for isolating pure cell populations from frozen tumors for transcriptional profiling and proves highly sensitive and specific. Use of this technique will allow a more focused approach to understanding tumor biology in vivo at a cellular and molecular level.
